Ligand raises FY25 adjusted EPS view $7.40-$7.65 from $6.70-$7.00

Consensus $6.86. Ligand (LGND) is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million, previously $200 million to $225 million, consensus $212.76M. Royalties are now anticipated to be in the range of $147 million to $157 million, previously $140 million to $150 million. Sales of Captisol are expected to be $40 million, previously $35 million to $40 million, and core contract revenue is anticipated to be $38 million, previously $25 million to $35 million.